April 23, 2012: Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
Liestal, Switzerland, April 23, 2012 - Santhera Pharmaceuticals (SIX: SANN) announced that all proposals at today's annual shareholders' meeting passed with a vast majority. Santhera's shareholders approved the annual report, the annual financial statements and the consolidated financial statements for 2011. Santhera's shareholders voted in favor of the proposed appropriation of the results, the renewal of authorized and the increase of conditional share capital. The annual shareholders' meeting also granted discharge to the members of the Board of Directors and management. Klaus Schollmeier and Timothy Rink were re-elected as Board members for a period of one and three years, respectively. The shareholders also re-elected Ernst & Young as auditors. A total of 1,691,639 shares or 46.05 % of the share capital was represented at the Annual Shareholders' Meeting.
In his presentation to shareholders, Thomas Meier, Chief Executive Officer, reported on significant progress with the Company's key projects and the impact of last year's restructuring: "In Europe, we submitted the application for marketing authorization of idebenone (Catena®) in Leber's Hereditary Optic Neuropathy (LHON). The revenues from product sales combined with strict cost control measures safeguarded Santhera's cash reserves." Looking into 2012 he continued: "We expect a decision from the European Medicines Agency on the LHON filing in the second half of the year. If approved, this would be our second product approval. With a significantly reduced cash burn the financing of Santhera's current business focus on key value drivers is secured into 2013."
* * *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan neuromuscular and mitochondrial diseases, areas of high unmet medical with no current therapies. Santhera's first product Catena® is currently marketed in Canada to treat Friedreich's Ataxia. Catena® is also under review for marketing authorization by the European Medicine Agency as the first therapy for patients suffering from Leber's Hereditary Optic Neuropathy. For further information, please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
Thomas Staffelbach, Vice President, Head Public & Investor Relations
Phone: +41 61 906 89 47
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.